Welcome to our dedicated page for Amedisys news (Ticker: AMED), a resource for investors and traders seeking the latest updates and insights on Amedisys stock.
Amedisys Inc. (NASDAQ: AMED) is a leading healthcare services company in the United States, specializing in delivering personalized home health, hospice, and high-acuity care services. Headquartered in Baton Rouge, LA, with an executive office in Nashville, TN, the company employs around 18,700 staff across 520 care centers in 37 states and the District of Columbia. Founded in 1982, Amedisys is dedicated to providing quality, clinically-distinctive care to more than 469,000 patients annually, with over 10.6 million visits each year.
Amedisys operates across four key segments: Home Health, Hospice, High Acuity Care, and Personal Care. The Home Health segment offers skilled nursing, therapy, and aid services directly in patients' homes, while the Hospice segment provides end-of-life care to terminally ill patients. The High Acuity Care segment delivers critical inpatient care elements at home, and the Personal Care segment, which was divested in March 2023, offered assistance with daily living activities.
Amedisys's commitment to high-quality care is underpinned by its comprehensive coordination with healthcare providers and personalized care plans tailored to each patient's unique needs. With a strong network involving more than 3,000 hospitals and 110,000 physicians nationwide, Amedisys is a trusted partner in post-acute care.
Recent notable achievements include a merger agreement with UnitedHealth Group, aimed at enhancing patient care through integrated services. Financially, Amedisys reported a net service revenue increase to $571.4 million for Q1 2024, reflecting a robust service demand despite divesting the Personal Care segment.
Additionally, Amedisys is actively involved in advancing healthcare technology. The company has partnered with Patient Choice Laboratories to incorporate advanced molecular testing, enhancing infection diagnosis and patient outcomes. This innovation underscores Amedisys’s commitment to leveraging cutting-edge technology to improve patient care.
For stakeholders, Amedisys remains a prominent figure in the home healthcare industry, constantly adapting and growing to meet the increasing needs of its patient population. The company's strategic partnerships and advancements in healthcare technology position it well for sustained growth and improved patient outcomes.
Amedisys (NASDAQ: AMED) reported its Q3 2024 financial results with net service revenue increasing to $587.7 million, up from $556.2 million in 2023. Net income was $16.9 million ($0.51 per diluted share), compared to $26.0 million ($0.79 per share) in 2023, including merger-related expenses of $16.7 million. For the nine-month period, revenue grew to $1,750.3 million from $1,665.6 million, with net income of $63.6 million compared to a net loss of $29.1 million in 2023. Adjusted EBITDA for Q3 2024 was $58.1 million, slightly up from $57.9 million in 2023.
Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, and high-acuity care, has been recognized by Strategic Healthcare Programs (SHP) for outstanding patient and caregiver satisfaction in 2023. 92 Amedisys care centers received SHPBest™ Patient Satisfaction Awards, with 14 centers earning Premier Performer status (top 5%) and 78 centers achieving Superior Performer status (top 20%). Notably, 13 care centers have maintained award-winning performance for five consecutive years.
The SHPBest™ award program evaluates over 3,200 home health providers and 1,750 hospice providers based on HHCAHPS and CAHPS Hospice survey satisfaction scores. This recognition highlights Amedisys' commitment to delivering exceptional care and maintaining high patient and caregiver satisfaction levels across its network.
Contessa Health, a subsidiary of Amedisys Inc. (Nasdaq: AMED), has been selected by the Centers for Medicare & Medicaid Services (CMS) to participate in the Guiding an Improved Dementia Experience (GUIDE) Model. This new Medicare alternative payment model aims to support people living with dementia and their caregivers. As one of nearly 400 participants, Contessa will build Dementia Care Programs (DCPs) to enhance care coordination and improve access to services.
The GUIDE Model, launched on July 1, 2024, will test a new payment approach for key supportive services, including comprehensive assessments, care coordination, 24/7 access to care team members, and respite services. Contessa's participation will provide dementia patients and caregivers with access to education, support, and respite services, potentially allowing them to live at home longer and achieve a better quality of life.
Amedisys, Inc. (NASDAQ: AMED) reported its financial results for Q2 2024. Net service revenue increased by $38.2 million to $591.2 million compared to Q2 2023. The company reported a net income of $32.3 million, including $11.9 million in merger-related expenses, compared to a net loss of $80.3 million in Q2 2023. Adjusted EBITDA was $73.2 million, slightly down from $74.6 million in 2023. For the six-month period, net service revenue rose to $1,162.6 million, with a net income of $46.7 million. The company's adjusted net income per diluted share for Q2 2024 was $1.32, compared to $1.37 in 2023. Amedisys noted that it will not conduct a quarterly earnings call due to its pending merger with UnitedHealth Group Incorporated.
FAQ
What is the current stock price of Amedisys (AMED)?
What is the market cap of Amedisys (AMED)?
What services does Amedisys Inc. provide?
Where is Amedisys Inc. headquartered?
How many employees does Amedisys have?
What is the scope of Amedisys's operations?
How many patients does Amedisys serve annually?
What recent merger has Amedisys entered into?
What recent technological advancement has Amedisys incorporated?
What was Amedisys's net service revenue for Q1 2024?
How does Amedisys coordinate patient care?
What was the Personal Care segment of Amedisys?
